Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Famitinib on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Famitinib is a targeted capsule for advanced cervical cancer, developed in China by Jiangsu Hengrui Pharmaceuticals and sold there as 艾比特®. It is not used on its own. It is always taken together with camrelizumab, an immunotherapy drip made by the same company.
China's National Medical Products Administration (NMPA) first approved the combination in May 2025, and in July 2026 it moved that approval from conditional to full and added a first-line use. Together with camrelizumab, it is approved for women with recurrent or metastatic cervical cancer:
It is a prescription cancer medicine and should only be used under a gynaecologic or medical oncologist.
Tumours need a steady blood supply to grow, and they send out signals that make new blood vessels sprout. Famitinib is a multi-target tyrosine kinase inhibitor: it blocks several of those signal receivers, including VEGFR2 and VEGFR3, and so starves the tumour of new vessels. This also changes the area around the tumour in a way that can help the immune system get in. Camrelizumab is a PD-1 antibody that takes the brakes off the immune system's T cells. The two are designed to work as a pair.
After platinum chemotherapy: in a randomised phase 2 trial published in the Journal of Clinical Oncology in 2025, women whose cervical cancer had come back after earlier treatment received famitinib with camrelizumab (105 women), camrelizumab alone (54) or chemotherapy (35). The tumour shrank in 41.0% with the pair against 24.1% with camrelizumab alone, as judged by independent reviewers. The disease was held back for a median of 8.1 months, compared with 4.1 months on camrelizumab alone and 2.9 months on chemotherapy, and median survival was 20.2 months against 14.9 and 13.9 months.
As a first treatment: the phase 3 trial SHR-1210-III-329 enrolled 443 women at 45 centres in China and compared the pair with platinum-based chemotherapy. Hengrui reports that it met all its main goals. In women whose tumours were PD-L1 positive, median survival was 35.8 months with the pair against 23.6 months with chemotherapy, a 36.6% lower risk of death.
In the phase 2 trial the doses were:
Your oncologist will set the exact dose and schedule from the Chinese prescribing information, and may lower the famitinib dose if side effects build up.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Severe side effects are common: this is a strong combination. In the phase 2 trial, 84.8% of women on famitinib with camrelizumab had at least one severe (grade 3 or higher) treatment-related side effect, and 16.2% stopped treatment because of side effects. In the first-line phase 3 trial, as reported at ESMO 2025, severe side effects occurred in 87.3% on the pair against 67.1% on chemotherapy. Close monitoring is part of the treatment plan.
Good to know: the published phase 2 results reported no fistulas and no vaginal bleeding linked to treatment, problems that have limited other blood-vessel-blocking tablets in cervical cancer.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The capsules can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either. Its partner, camrelizumab, is not approved in India or by the US FDA either, so both medicines are imported together for the same patient.
Patients can still get them legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For another option in cervical cancer that has come back after earlier treatment, see our page on Tivdak.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Because famitinib is only used with camrelizumab, we plan both together: the daily capsules for the patient, and the camrelizumab vials for the hospital, timed to the 3-weekly drip. Both travel in their sealed original packs under temperature-controlled shipping and should be stored as directed on each pack. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating hospital on a valid oncologist's prescription.
Gynaecologic oncology teams in Delhi treat women from across North India, and our New Delhi dispatch point keeps delivery times short.
Oncologists in Mumbai can request both medicines for a named patient once the reports are shared.
Capsules can go to the patient at home, while camrelizumab is delivered to the hospital where the drip is given.
A long-standing centre for women's cancer care in South India, used to importing medicines for individual patients.
We time each delivery to the 3-weekly camrelizumab cycle so treatment is not delayed.
Patients in Kolkata and the eastern states can use the same documented import route, with updates at each step.
The treating oncologist can send us the prescription and treatment history to begin the import.
Oncologists in Ahmedabad can arrange access for women newly diagnosed with recurrent disease or after chemotherapy.
Patients in Rajasthan can receive their supply close to home, as long as the import is in their name.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the treating hospital.
We coordinate delivery to cancer hospitals across Uttar Pradesh.
Patients across Kerala can receive both medicines at their hospital in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
